Literature DB >> 6475985

C-II anapolipoproteinemia and severe hypertriglyceridemia. Report of a rare case with absence of C-II apolipoprotein isoforms and review of the literature.

K Saku, C Cedres, B McDonald, B A Hynd, B W Liu, L S Srivastava, M L Kashyap.   

Abstract

A new case of C-II anapolipoproteinemia (complete apolipoprotein C-II deficiency) as the cause of severe hypertriglyceridemia with chylomicronemia (type I lipoprotein phenotype) is described. The patient was a five-year-old boy living in Connecticut. He had splenomegaly, episodic abdominal pain, and bloody stools. Absence of apolipoprotein C-II (and its isoforms C-II1 and C-II2) was documented by a sensitive and specific radioimmunoassay, analytical isoelectric focusing, and in vitro lipolytic assay. Decreased levels of high- and low-density lipoprotein cholesterol and apolipoproteins A-I and A-II and increased levels of plasma triglycerides and apolipoprotein E were found. Post-heparin extra-hepatic lipoprotein lipase activity was within normal range. Incorporation of exogenous purified human apolipoprotein C-II to an incubation mixture of purified lipoprotein lipase and the patient's triglyceride-rich lipoproteins resulted in a dramatic increase in the catabolic rate of the defective triglyceride-rich lipoproteins. The absence of the isoforms of apolipoprotein C-II in this patient indicates that a common gene exists for the C-II isoproteins, which appear to be necessary for normal triglyceride transport in humans. A literature review of 23 reported cases indicates that xanthomas and hepatosplenomegaly are less common in C-II anapolipoproteinemia than in lipoprotein lipase deficiency, the other major etiologic cause of genetic chylomicronemia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6475985     DOI: 10.1016/0002-9343(84)90102-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  12 in total

Review 1.  IDL, VLDL, chylomicrons and atherosclerosis.

Authors:  B G Nordestgaard; A Tybjaerg-Hansen
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

2.  A nonsense mutation in the apolipoprotein C-IIPadova gene in a patient with apolipoprotein C-II deficiency.

Authors:  S S Fojo; P Lohse; C Parrott; G Baggio; C Gabelli; F Thomas; J Hoffman; H B Brewer
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

3.  Primary lipoprotein-lipase-activity deficiency: clinical investigation of a French Canadian population.

Authors:  C Gagné; L D Brun; P Julien; S Moorjani; P J Lupien
Journal:  CMAJ       Date:  1989-02-15       Impact factor: 8.262

4.  Donor splice site mutation in the apolipoprotein (Apo) C-II gene (Apo C-IIHamburg) of a patient with Apo C-II deficiency.

Authors:  S S Fojo; U Beisiegel; U Beil; K Higuchi; M Bojanovski; R E Gregg; H Greten; H B Brewer
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

5.  Apo C-II deficiency type Bari.

Authors:  A Capurso; F Resta; F Turturro; A M Colacicco; C Crecchio; G Pepe
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

6.  Apolipoprotein CIISt. Michael. Familial apolipoprotein CII deficiency associated with premature vascular disease.

Authors:  P W Connelly; G F Maguire; J A Little
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

7.  A novel type hypertriglyceridemia observed in FLS mice.

Authors:  Masaya Takahashi; Toshiji Saibara; Yoshihisa Nemoto; Masafumi Ono; Naoaki Akisawa; Shinji Iwasaki; Katsumi Toda; Yasuhiro Ogawa; Akihiko Wakatsuki; Shuichiro Inagaki; Saburo Onishi
Journal:  Lipids       Date:  2003-07       Impact factor: 1.880

8.  Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.

Authors:  G Baggio; E Manzato; C Gabelli; R Fellin; S Martini; G B Enzi; F Verlato; M R Baiocchi; D L Sprecher; M L Kashyap
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

9.  Structure of apolipoprotein C-IIToronto, a nonfunctional human apolipoprotein.

Authors:  P W Connelly; G F Maguire; T Hofmann; J A Little
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

10.  Mechanism of action of gemfibrozil on lipoprotein metabolism.

Authors:  K Saku; P S Gartside; B A Hynd; M L Kashyap
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.